SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq:PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that it will change its name to Biora Therapeutics, Inc. during the second quarter of 2022, to better reflect the company’s focus on developing its pipeline for targeted and systemic oral delivery of biotherapeutics.
Progenity to Become Biora Therapeutics as it Completes Transformation
Globe Newswire -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here